While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Real-time index price for TSX Buyback Index (TXBB), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk (NVO) announced Friday that the U.S. Food and Drug Administration (FDA) accepted its marketing application for ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of researchers has now discovered it can also do wonders for people who have ...